News & Events

Riboxx Pharmaceuticals and China National Biotec Group Company Limited initiate a collaboration

Riboxx Pharmaceuticals and China National Biotec Group Company Limited initiate a collaboration to evaluate the potential of Riboxxim®, a TLR3 agonist, as adjuvant in a vaccine to treat a deadly infectious disease

Weiterlesen …

Riboxx Pharmaceuticals announces the set-up of a Regulatory Affairs and GMP Manufacturing Advisory Committee

Radebeul, Germany, 7th May 2013 – Riboxx Pharmaceuticals GmbH (Riboxx) today announced that it has established a Regulatory Affairs and GMP Manufacturing Advisory Committee consisting of experts from the respective fields with the aim to perform clinical safety studies on its novel Toll-Like Receptor 3 agonist, Riboxxim®.

Weiterlesen …

Riboxx Announces RNA Manufacturing Patent Grant by EPO - Novel process for the manufacturing of double-stranded RNA results in increased stability in biological fluids

Radebeul, Germany, 17th July 2013 – Riboxx Pharmaceuticals GmbH (Riboxx) today announced that the European Patent Office (EPO) has granted a patent on a novel process for the manufacturing of double-stranded RNA (dsRNA) bearing chemical modifications. This is the third patent granted by EPO for Riboxx’s technologies so far.

Weiterlesen …

Journal of Immunology Research published a Research Article of Naumann et al. entitled "Activation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100"

Radebeul, Germany, 03rd December 2013 – Journal of Immunology Research published a Research Article of Naumann et al. entitled "Activation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100". The full paper can be downloaded under the following link: http://www.hindawi.com/journals/cdi/2013/283649/

Weiterlesen …

Cookies erleichtern die Bereitstellung unserer Dienste. Mit der Nutzung unserer Dienste erklären Sie sich damit einverstanden, dass wir Cookies verwenden.